Shannuo Li, MS
Multi-Antigen T Cell Hybridizers (MATCH) for Precision Immunotherapy
Abstract
The Multi-Antigen T Cell Hybridizer (MATCH) is a modular immunotherapy platform that uses a two-part system to redirect T cells to cancerous B cells. One component targets tumor-specific antigens, while the other binds and activates T cells. These components assemble in vivo via complementary morpholino oligonucleotides (MORFs), functioning like molecular “Legos” to form localized immune synapses. This design allows personalized targeting by mixing Fab’ fragments matched to a patient’s unique cancer profile. By applying pre-targeting/ post-assembly approach, MATCH can also reduce the risk of severe side effects such as cytokine release syndrome and T cell exhaustion with optimizing PKPD profile. It has shown promising results in animal models in multiple myeloma cell bearing mice and patient’s bone marrow samples by using patient’s own T cells.
The PhRMA Foundation award empowers me to advance translational immunotherapy research on Multi-Antigen T Cell Hybridizers (MATCH), bringing innovative, patient-focused treatments closer to the clinic.
